Systemic Therapy for Melanoma: American Society of Clinical Oncology Guideline (ASCO)

ASCO make recommendations for systemic treatment in the adjuvant and unresectable/metastatic setting, for patients with resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma or BRAF-mutant disease.

Journal of Clinical Oncology